JP2004505965A5 - - Google Patents

Download PDF

Info

Publication number
JP2004505965A5
JP2004505965A5 JP2002518202A JP2002518202A JP2004505965A5 JP 2004505965 A5 JP2004505965 A5 JP 2004505965A5 JP 2002518202 A JP2002518202 A JP 2002518202A JP 2002518202 A JP2002518202 A JP 2002518202A JP 2004505965 A5 JP2004505965 A5 JP 2004505965A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
formula
salt
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002518202A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004505965A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2001/003561 external-priority patent/WO2002012227A2/en
Publication of JP2004505965A publication Critical patent/JP2004505965A/ja
Publication of JP2004505965A5 publication Critical patent/JP2004505965A5/ja
Pending legal-status Critical Current

Links

JP2002518202A 2000-08-09 2001-08-08 化合物 Pending JP2004505965A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00402257 2000-08-09
PCT/GB2001/003561 WO2002012227A2 (en) 2000-08-09 2001-08-08 Indole, azaindole and indazole derivatives having vegf inhibiting activity

Publications (2)

Publication Number Publication Date
JP2004505965A JP2004505965A (ja) 2004-02-26
JP2004505965A5 true JP2004505965A5 (enExample) 2005-03-17

Family

ID=8173808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002518202A Pending JP2004505965A (ja) 2000-08-09 2001-08-08 化合物

Country Status (14)

Country Link
US (2) US20030207878A1 (enExample)
EP (1) EP1311500A2 (enExample)
JP (1) JP2004505965A (enExample)
KR (1) KR20030029812A (enExample)
CN (1) CN1245402C (enExample)
AU (2) AU2001279938B2 (enExample)
BR (1) BR0113078A (enExample)
CA (1) CA2416525A1 (enExample)
IL (1) IL154034A0 (enExample)
MX (1) MXPA03000874A (enExample)
NO (1) NO20030628L (enExample)
NZ (1) NZ523987A (enExample)
WO (1) WO2002012227A2 (enExample)
ZA (1) ZA200300489B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05708B1 (et) 1999-02-10 2014-04-15 Astrazeneca Ab Kinasoliini derivaat angiogeneesi inhibiitorina ja selle kasutamine
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
ATE300303T1 (de) 2000-03-06 2005-08-15 Astrazeneca Ab Verwendung von quinazolinderivate als inhibitoren der angiogenese
CN1240688C (zh) 2000-04-07 2006-02-08 阿斯特拉曾尼卡有限公司 喹唑啉化合物
WO2003064413A1 (en) 2002-02-01 2003-08-07 Astrazeneca Ab Quinazoline compounds
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
TWI272271B (en) * 2002-07-19 2007-02-01 Bristol Myers Squibb Co Process for preparing certain pyrrolotriazine compounds
JP4560483B2 (ja) * 2002-10-03 2010-10-13 ターゲジェン インコーポレーティッド 血管静態化物質およびそれらの使用法
KR101089462B1 (ko) 2002-11-04 2011-12-07 아스트라제네카 아베 Src 티로신 키나제 억제제로서의 퀴나졸린 유도체
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
ATE458731T1 (de) 2002-12-20 2010-03-15 Pfizer Prod Inc Pyrimidin-derivate zur behandlung von anormalem zellwachstum
AU2004218412A1 (en) 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
WO2004103159A2 (en) * 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
BRPI0511132A (pt) 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina e composição farmacêutica compreendendo os mesmos
WO2005111022A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
BRPI0510963A (pt) 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
US7851623B2 (en) 2006-11-02 2010-12-14 Astrazeneca Ab Chemical process
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
BRPI1006115A8 (pt) 2009-01-19 2017-09-26 Abbott Lab "agentes indutores de apoptose para o tratamento de câncer e doenças autoimunes".
WO2010096338A1 (en) * 2009-02-23 2010-08-26 Merck Sharp & Dohme Corp. PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
US8653079B2 (en) 2011-08-15 2014-02-18 Merck Sharp & Dohme Corp. Pyrazolo [4,3-C] cinnolin-3-one M1 receptor positive allosteric modulators
MX383300B (es) 2014-06-19 2025-03-13 Boehringer Ingelheim Animal Health Usa Inc Composiciones parasiticidas que comprenden derivados de indol, metodos y usos de los mismos.
CN116406271B (zh) * 2020-07-14 2024-09-24 南京再明医药有限公司 双环类化合物
CA3213079A1 (en) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Amino-substituted heterocycles for treating cancers with egfr mutations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3987332A (en) * 1975-10-09 1976-10-19 Varian Associates Gang tuner for multi-cavity klystron
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5237629A (en) * 1992-03-19 1993-08-17 The United States Of America As Represented By The United States Department Of Energy Digitally controlled distributed phase shifter
US5440270A (en) * 1992-07-14 1995-08-08 Linear Technology Corporation Linear-phase filter having high gain selectivity
SE9302453L (sv) * 1993-07-20 1994-10-17 Telia Ab Förfarande och anordning för synkronisering i digitalt transmissionssystem av typen OFDM
TW414798B (en) * 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JP3727406B2 (ja) * 1996-03-07 2005-12-14 株式会社日立国際電気 関数変換演算器
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AU733551B2 (en) * 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2001522853A (ja) * 1997-11-11 2001-11-20 ファイザー・プロダクツ・インク 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体
JPH11259454A (ja) * 1998-03-09 1999-09-24 Sharp Corp フーリエ変換装置
DE69942097D1 (de) * 1998-08-11 2010-04-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
US20030162795A1 (en) * 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
KR200212866Y1 (ko) * 1998-12-26 2001-02-15 서평원 선왜곡 방식 전력증폭기용 능동 왜곡신호 발생회로
US6982265B1 (en) * 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
ATE318603T1 (de) * 1999-05-21 2006-03-15 Bristol Myers Squibb Co Pyrrolotriazin kinasehemmer
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
PT1287001E (pt) * 2000-06-06 2004-12-31 Pfizer Prod Inc Derivados de tiofeno uteis como agentes anticancerigenos

Similar Documents

Publication Publication Date Title
JP2004505965A5 (enExample)
CA2398682A1 (en) Phosphonium and imidazolium salts and methods of their preparation
JP2004533467A5 (enExample)
JP2006508903A5 (enExample)
JP2002542342A5 (enExample)
JP2005525427A5 (enExample)
EP1826196A3 (en) Vinyl ether compounds
JP2004535412A5 (enExample)
JPH09301934A5 (enExample)
EP1279665A3 (en) A process for the preparation of perindopril, its analogous compounds and salts thereof using 2,5-dioxo-oxazolidine intermediate compounds
JP2006523241A5 (enExample)
EP1849788A8 (en) Organosilicon compound
EP2088142A3 (en) Dihydropyrimidines, process for their preparation and use thereof.
JP2005519149A5 (enExample)
RU2006121438A (ru) Способ получения бисфосфолановых лигандов
JP2007538042A5 (enExample)
CA2334821A1 (en) Chemical synthesis of morpholine derivatives
JP2005526149A5 (enExample)
EP0357404A3 (en) Process for the preparation of cyclopentane derivatives
JP2006524231A5 (enExample)
WO2003024958A3 (en) Processes for the preparation of 1,5-diaryl-3-substituted-pyrazoles
JP2005536557A5 (enExample)
JP2012530113A5 (enExample)
JPH09227486A5 (enExample)
JP2004537638A5 (enExample)